Abstract:The loss of dopaminergic neurons in the substantia nigra is a hallmark of pathology in Parkinson’s disease (PD). Dimethylarginine dimethylaminohydrolase-1 (DDAH-1) is the critical enzyme responsible for the degradation of asymmetric dimethylarginine (ADMA) which inhibits nitric oxide (NO) synthase and has been implicated in neurodegeneration. Mitochondrial dysfunction, particularly in the mitochondria-associated endoplasmic reticulum membrane (MAM), plays a critical role in this process, although the specific molecular target has not yet been determined. This study aims to examine the involvement of DDAH-1 in the nigrostriatal dopaminergic pathway and PD pathogenesis. The distribution of DDAH-1 in the brain and its colocalization with dopaminergic neurons were observed. The loss of dopaminergic neurons and aggravated locomotor disability after rotenone (ROT) injection were showed in the DDAH-1 knockout rat. l-arginine (ARG) and NO donors were employed to elucidate the role of NO respectively. In vitro, we investigated the effects of DDAH-1 knockdown or overexpression on cell viability and mitochondrial functions, as well as modulation of ADMA/NO levels using ADMA or ARG. MAM formation was assessed by the Mitofusin2 oligomerization and the mitochondrial ubiquitin ligase (MITOL) phosphorylation. We found that DDAH-1 downregulation resulted in enhanced cell death and mitochondrial dysfunctions, accompanied by elevated ADMA and reduced NO levels. However, the recovered NO level after the ARG supplement failed to exhibit a protective effect on mitochondrial functions and partially restored cell viability. DDAH-1 overexpression prevented ROT toxicity, while ADMA treatment attenuated these protective effects. The declines of MAM formation in ROT-treated cells were exacerbated by DDAH-1 downregulation via reduced MITOL phosphorylation, which was reversed by DDAH-1 overexpression. Together, the abundant expression of DDAH-1 in nigral dopaminergic neurons may exert neuroprotective effects by maintaining MAM formation and mitochondrial function probably via ADMA, indicating the therapeutic potential of targeting DDAH-1 for PD.

Function and Regulation of ALDH1A1-Positive Nigrostriatal Dopaminergic Neurons in Motor Control and Parkinson’s Disease

Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson’s disease

Aldehyde Dehydrogenase 1 Defines and Protects a Nigrostriatal Dopaminergic Neuron Subpopulation.

A Primate Nigrostriatal Atlas of Neuronal Vulnerability and Resilience in a Model of Parkinson’s Disease

Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson’s disease

DDAH-1 Maintains Endoplasmic Reticulum-Mitochondria Contacts and Protects Dopaminergic Neurons in Parkinson’s Disease

ALDH1A1 Regulates Postsynaptic Μ–opioid Receptor Expression in Dorsal Striatal Projection Neurons and Mitigates Dyskinesia Through Transsynaptic Retinoic Acid Signaling

DDAH-1 maintains endoplasmic reticulum-mitochondria contacts and protects dopaminergic neurons in Parkinson's disease

Tonic dendritic GABA release by substantia nigra dopaminergic neurons

Dopaminergic modulation of striatal function and Parkinson’s disease

Integrating the Roles of Midbrain Dopamine Circuits in Behavior and Neuropsychiatric Disease

Calbindin and Girk2/Aldh1a1 define resilient vs vulnerable dopaminergic neurons in a primate Parkinson's disease model

Non-coding RNAs as therapeutic targets in Parkinson's Disease: A focus on dopamine

Dopamine Signaling in Substantia Nigra and Its Impact on Locomotor Function—Not a New Concept, but Neglected Reality

Nmda Receptor Regulation of Levodopa-Induced Behavior and Changes in Striatal G Protein-Coupled Receptor Kinase 6 and Beta-Arrestin-1 Expression in Parkinsonian Rats

Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression

Dopamine modification of glycolytic enzymes impairs glycolysis: possible implications for Parkinson's disease

Primary Cilia in Parkinson’s Disease: Summative Roles in Signaling Pathways, Genes, Defective Mitochondrial Function, and Substantia Nigra Dopaminergic Neurons

Dopamine Release Neuroenergetics in Mouse Striatal Slices

Roles of Glutamate Receptors in Parkinson’s Disease

Molecular profiling of human substantia nigra identifies diverse neuron types associated with vulnerability in Parkinson's disease